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associated diarrhea.
Administration of GSB was well tolerated and safe, and with
no associated fungemia. The administration of GSB in the
immediate pre-transplant period did not impact LOS, inci-
dence and severity of mucositis, or incidence and volume of
diarrhea. Complete analysis and subgroup analysis are being
performed and will be presented at the meeting.
318
Immunogenecity of Early Post Transplant Vaccination in
Children
Micah Skeens 1, Monica Ardura 2, Rajinder Bajwa 3,
Thomas Gross 4, Kristen Mccrea 5, Sandeep Soni 6. 1 Bone
Marrow Transplant, Nationwide Childrens, Columbus, OH;
2 Infectious Disease, Nationwide Children's, Columbus, OH;
3 Bone Marrow Transplantation, Nationwide Children's,
Columbus, OH; 4Hematology/Oncology/BMT, Nationwide
Children's Hospital, Columbus, OH; 5 Bone Marrow Transplant,
Nationwide Children's Hospital; 6 Division of Heme/Onc/BMT,
Nationwide Children's Hospital, Columbus, OH
Background: Vaccine-preventable diseases continue to pose
a risk to HSCT recipients, thus guidelines recommend routine
vaccination after HSCT. Pediatric data is limited regarding
vaccine immunogenicity post-HSCT and may contribute to
inconsistent vaccination practices.
Objective: Prospective, observational study to determine the
immunogenicity of hepatitis B, tetanus, and pneumococcal
vaccination in children after HSCT. Secondary objective was
to evaluate correlation with T&B cell numbers.
Patients and Methods: Children receiving a HSCT from
January 2010 thru October 2012were prospectively followed.
Three doses of Hepatitis, PCV 13, and Pentacel were given per
guidelines two months apart. Pre and post vaccine-speciﬁc
antibodies and T&B cell studies were performed at 6 and 12
months post-HSCT.
Results: Compliance with current vaccine recommendations
occurred in 15 of 33 (45 %) subjects. Of the 15 subjects, 12
were evaluable receiving vaccinations and lab draws
according to the predeﬁned schedule. Patient characteristics
are described in Table 1.
Time to immunization post HSCT was a median of 197
days [180-404]. 2/12 subjects were chronic GVHD patients on
immunosuppression at the time of re-vaccination. One of
these patients did not respond to vaccination. Protective
antibody levels were found for tetanus in 83% of subjects
(median of 2.6 IU/mL [range 0.1-7]) and 69% of patients for
hepatitis. 4 evaluable subjects responded to at least 1Table 1
Patient Characteristics
Male 8 (62%)
Age at transplant 7.8 (0.6-18.9)
Transplant Type
Allogeneic 11 (85%)
Autologous 2 (15%)
Donor Source
Bone marrow 7 (54%)
Peripheral blood 3 (23%)
Umbilical cord blood 3 (23%)
Preparative Regimen
Myeloablative 10 (77%)
Serotherapy 6 (60%)
Non-myeloblative 3 (23%)
Serotherapy 2 (67%)
GVHD Prophylaxis
CNI/MTX 6 (60%)
CNI/MMF 4 (40%)pneumococcal serotype, 2 of 4 (50%) to at least 6 serotypes;
3, 4, 6B, and 19F were most immunogenic. There was no
correlation between total peripheral WBC or CD3, CD8, CD19
numbers and tetanus antibody concentrations.
Conclusions: Despite the small sample size in our cohort,
hepatitis, tetanus, and pneumococcal vaccination was
immunogenic in a majority of subjects when given 6 months
post HSCT. Pneumococcal serotypes cited to cause invasive
disease post HSCT were most immunogenic, but additional
data is needed.319
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Advances in autologous and allogeneic hematopoietic stem
cell transplantation (HSCT) over the past 20 years may have
had an impact on the morbidity and mortality associated
with infections post-transplant. We sought to retrospectively
analyze the epidemiology and risk factors for bacterial,
fungal, viral, and parasitic infections 0-30 days post-trans-
plant in a cohort of 385 autologous and 759 allogeneic
pediatric HSCT recipients transplanted in a single institution
between1990 to 2009. Risk factors were evaluated using
logistic regression. Infections occurred in 98 (25%) autolo-
gous compared to 307 (40%) allogeneic HSCT patients. Gram-
positive bacterial infections were more prevalent than gram-
negative bacterial infections in both autologous (P ¼ .003)
and allogeneic (P < .0001) HSCT patients. Bacteremia
occurred in 31 (8%) autologous and 59 (8%) allogeneic HSCT
patients. Autologous HSCT patients with a diagnosis of
leukemia were at a higher risk for bacterial infections
compared to those with solid tumors (P ¼ .004, OR 2.80, 95%
CI 1.39-5.66). Infections due to fungal and parasitic patho-
gens in autologous HSCT patients were uncommon, and
occurred exclusively prior to 2000. Candidemiawas detected
in 26 (3%) and aspergillosis in 49 (6%) allogeneic recipients.
Herpes-Simplex virus was the most common cause of viral
infections in both autologous and allogeneic recipients.
Cytomegalovirus donor/recipient status increased risk for all
viral infections for allogeneic HSCT recipients (P ¼ .0004).
Only 3 (0.8%) deaths were attributed to infection after
autologous HSCT. All occurred prior to 2000 in patients
transplanted for acute myeloid leukemia. There were 8 (1%)
allogeneic HSCT patients who died of infections 0-30 days
post-transplant. This is the largest retrospective study on the
changing epidemiology of infections after autologous and
allogeneic HSCT in children and adolescents.320
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